Skip to search formSkip to main content

PPI-0903

Known as: PPI0903 
 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Cephalosporins

Narrower (3)

TAK-599Teflaroceftaroline fosamil

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Ceftaroline Fosamil—A New Broad-Spectrum Cephalosporin with Significant Activity against Methicillin-Resistant Staphylococci
Ceftaroline fosamil (PPI-0903, TAK-599, Teflaro®, Forest Pharmaceuticals) is the prodrug for ceftaroline (T-91825), a broad… Expand
  • table 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2007
2007
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
BACKGROUND Ceftaroline (PPI-0903M, T-91825) is a novel cephalosporin, administered as an N-phosphono prodrug. We investigated its… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2007
2007
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus…
Using the rabbit endocarditis model, we compared the activity of a new broad-spectrum cephalosporin, ceftaroline, with those of… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.
Ceftaroline, the bioactive metabolite of ceftaroline fosamil (previously PPI-0903, TAK-599), is a broad-spectrum cephalosporin… Expand
Is this relevant?
Review
2007
Review
2007
Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.
Ceftobiprole is the first of the investigational beta-lactam antibiotics with in vitro activity against methicillin-resistant… Expand
Is this relevant?
2007
2007
Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy
Ceftobiprole is the first of the investigational β-lactam antibiotics with in vitro activity against methicillin-resistant… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo…
PPI-0903 is a new cephalosporin with broad-spectrum activity, including beta-lactam-resistant Streptococcus pneumoniae and… Expand
  • table 2
  • table 1
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
Review
2006
Review
2006
Anti-MRSA beta-lactams in development.
Ceftobiprole medocaril, the most advanced of the anti-MRSA (methicillin-resistant Staphylococcus aureus) beta-lactams in clinical… Expand
Is this relevant?
2006
2006
Anti-MRSA β-lactams in development
Ceftobiprole medocaril, the most advanced of the anti-MRSA (methicillin-resistant Staphylococcus aureus ) β-lactams in clinical… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.
PPI-0903M is a novel N-phosphono-type cephalosporin active against oxacillin-resistant staphylococci and many other gram-positive… Expand
Is this relevant?